NuCana (NASDAQ:NCNA) Posts Quarterly Earnings Results, Beats Estimates By $2.18 EPS

NuCana (NASDAQ:NCNA) announced its quarterly earnings data on Thursday. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.65) by $2.18, Zacks reports.

NuCana Trading Down 1.0%

NASDAQ:NCNA traded down $0.01 during trading hours on Thursday, hitting $0.93. The company’s stock had a trading volume of 26,467 shares, compared to its average volume of 27,888. NuCana has a 52-week low of $0.88 and a 52-week high of $4.55. The stock has a fifty day moving average of $1.14 and a 200-day moving average of $1.66. The stock has a market capitalization of $3.87 million, a P/E ratio of -0.24 and a beta of 2.39.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

NuCana Company Profile

NuCana plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company uses its ProTide technology to create nucleotide analog medicines designed to improve the delivery and activity of existing chemotherapy agents while addressing mechanisms that can limit treatment effectiveness. NuCana’s development portfolio has included NUC-1031, also known as Acelarin, a ProTide form of gemcitabine evaluated in several solid tumors. The company has also advanced NUC-3373, a ProTide-based fluoropyrimidine designed to deliver the active component of 5-fluorouracil, and NUC-7738, an investigational cancer therapy based on a nucleoside analog.